Genomic-based biomarkers of drug-induced nephrotoxicity

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 1, 2006, Pages 95-101

  Davis, John W ^a   Kramer, Jeffrey A ^b  

^a PFIZER INC   (United States)

^b LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

Gene expression; Genomic biomarkers; Nephrotoxicity; Quantitative real time PCR; Toxicogenomics

Indexed keywords

BIOLOGICAL MARKER; NOTCH1 RECEPTOR;

FOOD AND DRUG ADMINISTRATION; GENETIC TRANSCRIPTION; GENOMICS; NEPHROTOXICITY; NONHUMAN; REVIEW; TOXICOGENETICS;

ANIMALS; GENETIC MARKERS; GENOMICS; HUMANS; KIDNEY DISEASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACEUTICAL PREPARATIONS; TOXICOGENETICS;

PRIMATES; RODENTIA;

EID: 33846301110     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.1.95     Document Type: Review

References (40)

1. HUANG Q, DUNN RT, JAYADEV S et al.: Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol. Sci. (2001) 63(2):196-207. Compared gene expression profiles in rats treated with cisplatin against those treated with an inactive isomer.
2. PETRICOIN EF 3rd, HACKETT JL, LESKO LJ et al.: Medical applications of microarray technologies: a regulatory science perspective. Nat. Genet. (2002) 32(Suppl.):474-479.
3. AMIN RP, VICKERS AE, SISTARE F et al.: Identification of putative gene based markers of renal toxicity. Environ. Health Perspect. (2004) 112(4):465-479. Compared gene expression profiles against three distinct classes of nephrotoxicants.
4. KRAMER JA, PETTIT SD, AMIN RP et al.: Overview on the application of transcription profiling using selected nephrotoxicants for toxicology assessment. Environ. Health Perspect. (2004) 112(4):460-464.
5. SEARFOSS GH, JORDAN WH, CALLIGARO DO et al.: Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J. Biol. Chem. (2003) 278(46):46107-46116.
6. GOODSAID FM: Genomic biomarkers of toxicity. Curr. Opin. Drug Discov. Devel. (2003) 6(1):41-49.
7. HAMADEH HK, KNIGHT BL, HAUGEN AC et al.: Methapyrilene toxicity: anchorage of pathologic observations to gene expression alterations. Toxicol. Pathol. (2002) 30(4):470-482.
8. THUKRAL SK, NORDONE PJ, HU R et al.: Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. Toxicol. Pathol. (2005) 33(3):343-355.
9. BARTOSIEWICZ MJ, JENKINS D, PENN S, EMERY J, BUCKPITT A: Unique gene expression patterns in liver and kidney associated with exposure to chemical toxicants. J. Pharmacol. Exp. Ther. (2001) 297(3):895-905.
10. THOMAS RS, RANK DR, PENN SG et al.: Identification of toxicologically predictive gene sets using cDNA microarrays. Mol. Pharmacol. (2001) 60(6):1189-1194.
11. HAMADEH HK, BUSHEL PR, JAYADEV S et al.: Gene expression analysis reveals chemical-specific profiles. ToxicoL Sci. (2002) 67(2):219-231.
12. SARTOR M, SCHWANEKAMP J, HALBLEIB D et al.: Microarray results improve significantly as hybridization approaches equilibrium. Biotechniques (2004) 36(5):790-796.
13. WERNER M, COSTA MJ, MITCHELL LG, NAYAR R: Nephrotoxicity of xenobiotics. Clin. Chim. Acta (1995) 237(1-2):107-154.
14. KHAN KNAA CL: Kidney. In: Handbook of Toxicological Pathology. WM Haschek, CG Rousseaux, MA Wallig (Eds), Academic Press, San Diego, US (2002):255-336. Comprehensive review of nephrotoxicants.
15. LOEB WF: The measurement of renal injury. Toxicol. Pathol. (1998) 26(1):26-28.
16. STAR RA: Treatment of acute renal failure. Kidney Int. (1998) 54(6):1817-1831.
17. HAN WK, BAILLY V, ABICHANDANI R, THADHANI R, BONVENTRE JV: Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. (2002) 62(1):237-244.
18. CHARLWOOD J, SKEHEL JM, KING N et al.: Proteomic analysis of rat kidney cortex following treatment with gentamicin. J. Proteome. Res. (2002) 1(1):73-82. This paper was the first to measure KIM-1 in the urine of patients with acute renal failure.
19. AICHER L, WAHL D, ARCE A, GRENET O, STEINER S: New insights into cyclosporine A nephrotoxicity by proteome analysis. Electrophoresis (1998) 19(11):1998-2003.
20. PRICE RG, TAYLOR SA, CHIVERS I et al.: Development and validation of new screening tests for nephrotoxic effects. Hum. Exp. Toxicol. (1996) 15(Suppl. 1):S10-S19.
21. HOUGHTON DC, LEE D, GILBERT DN, BENNETT WM: Chronic gentamicin nephrotoxiciry. Continued tubular injury with preserved glomerular filtration function. Am. J. Pathol. (1986) 123(1):183-194.
22. MINGEOT-LECLERCQ MP, TULKENS PM: Aminoglycosides: nephrotoxicity. Antimicrob. Agents Chemother. (1999) 43(5):1003-1012.
23. THOMPSON KL, AFSHARI CA, AMIN RP et al.: Identification of platform-independent gene expression markers of cisplatin nephrotoxicity. Environ. Health Perspect. (2004) 112(4):488-494. This is a cross-platform characterisation of cisplatin-induced gene expression changes.
24. SAFIRSTEIN RL: Acute renal failure: from renal physiology to the renal transcriptome. Kidney Int. Suppl. (2004) 91:S62-S66.
25. YOSHIDA T, KURELLA M, BEATO F et al.: Monitoring changes in gene expression in renal ischemia-reperfusion in the rat. Kidney Int. (2002) 61(5):1646-1654.
26. NAHM O, WOO SK, HANDLER JS, KWON HM: Involvement of multiple kinase pathways in stimulation of gene transcription by hypertonicity. Am. J. Physiol. Cell. Physiol. (2002) 282(1):C49-C58.
27. LUHE A, HILDEBRAND H, BACH U, DINGERMANN T, AHR HJ: A new approach to studying ochratoxin A (OTA)-induced nephrotoxicity: expression profiling in vivo and in vitro employing cDNA microarrays. Toxicol. Sci. (2003) 73(2):315-328.
28. WALKER R: Risk assessment of ochratoxin: current views of the European Scientific Committee on Food, the JECFA and the Codex Committee on Food Additives and Contaminants. Adv. Exp. Med. Biol. (2002) 504:249-255.
29. DAVIS JW 2nd, GOODSAID FM, BRAL CM et al.: Quantitative gene expression analysis in a nonhuman primate model of antibiotic-induced nephrotoxicity. Toxicol. Appl. Pharmacol. (2004) 200(1):16-26. This was the first published attempt to correlate gene expression changes in rats in a nonhuman primate model of drug-induced nephrotoxicity.
30. BAILLY V, ZHANG Z, MEIER W et al.: Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J. Biol. Chem. (2002) 277(42):39739-39748.
31. ETI S, CHENG CY, MARSHALL A, REIDENBERG MM: Urinary clusterin in chronic nephroroxicity in the rat. Proc. Soc. Exp. Biol. Med. (1993) 202(4):487-490. The authors proposed clusterin as a urinary protcomic marker of nephrotoxicity in rats.
32. ROSENBERG ME, SILKENSEN J: Clusterin and the kidney. Exp. Nephrol. (1995) 3(1):9-14.
33. VICKERS AE, ROSE K, FISHER R et al.: Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol. Pathol. (2004) 32(5):577-590. This paper demonstrates the potential of using kidney slices as a genomics-based screening tool.
34. STORCK T, VON BREVERN MC, BEHRENS CK, SCHEEL J, BACH A: Transcriptomics in predictive toxicology. Curr. Opin. Drug Discov. Devel. (2002) 5(1):90-97.
35. LINDON JC, NICHOLSON JK, HOLMES E et al.: Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol. Appl. Pharmacol. (2003) 187(3):137-146.
36. KOOP R: Combinatorial biomarkers: from early toxicology assays to patient population profiling. Drug Discov. Today (2005) 10(11):781-788.
37. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html Challenge and opportunity on the critical path to new medical products.
38. http://www.fda.gov/cder/guidance/6400fnl.pdf Guidance forindustry: pharmacogenomic data submissions. A guidance document from the FDA that established and encouraged voluntary submission of genomics data.
39. http://www.ensembl.org/index.html
40. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=genomeprj